Dubai firm sells Tunisian pharmaceutical company to Recordati
Dubai-based Abraaj Group has sold its stake in Tunisian pharmaceutical company Opalia Pharma to international pharmaceutical company Recordati.
The deal was part of Recordatis acquisition of about 67 per cent of Opalias share capital held by non-Tunisian investors, which was sold for a total of 22.6m ($31.1m). The Italian stock exchange-listed firm is looking at acquiring another 23 per cent of the company in the coming months.
Abraaj was advised by Frances Societe Generale Corporate and Investment Banking, the UKs Freshfields Bruckhaus Deringer, and Tunisias Meziou, Knani & Khlif on the deal.
The private equity investor bought its stake in Tunisias third-largest local pharmaceutical company in 2009, marking its first purchase in the Tunisian market.
Abraaj is increasingly eyeing Africa for returns. In June, it announced it had invested a total of $2.2bn in 69 companies on the continent. Another was added to that list in October, when Abraaj invested in African Industrial Services Group, an Ivory Coast-based engineering services and component manufacturing and distribution firm.
You might also like...
Algeria signs oil deal with Swedish company
19 April 2024
Masdar and Etihad plan pumped hydro project
19 April 2024
Ewec signs Ajban solar PV contract
19 April 2024
Contractor orders compressors for onshore project
18 April 2024
A MEED Subscription...
Subscribe or upgrade your current MEED.com package to support your strategic planning with the MENA region’s best source of business information. Proceed to our online shop below to find out more about the features in each package.